Search
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalThis drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Glycerin
go.drugbank.com/drugs/DB09462ApprovedInvestigationalA trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Products: Honest Cleansing Foa M, Allvit Skin Lighting Cleansing Foa mFordadistrogene movaparvovec
go.drugbank.com/drugs/DB16800InvestigationalSynonyms: DNA (RECOMBINANT ADENO-ASSOCIATED VIRUS 9 VECTOR PF-06939926 HUMAN MUSCLE-SPECIFIC ENHANCER/PROMOTER PLUS HUMAN MINI-DYSTROPHIN GENE PLUS ADENO-ASSOCIATED VIRUS 9 INVERTED TERMINAL REPEAT FLANKS)Lormetazepam
go.drugbank.com/drugs/DB13872ApprovedIt is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label].
Categories: Peripheral Opioid Receptor AntagonistsPCO-371
go.drugbank.com/drugs/DB14946InvestigationalPCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).
Synonyms: non-peptide small molecule orally available agonist of the parathyroid hormone receptor type IBotaretigene sparoparvovec
go.drugbank.com/drugs/DB16814InvestigationalSynonyms: VIRUS 5 VECTOR AAV-RPGR HUMAN RHODOPSIN KINASE PROMOTER FRAGMENT-REGULATED HUMAN RETINITIS PIGMENTOSA GTPASE REGULATOR RPGR-ORF15 ISOFORM GENE VARIANT PLUS ADENO-ASSOCIATED VIRUS 2 INVERTED TERMINAL REPEATBrenetafusp
go.drugbank.com/drugs/DB19441InvestigationalBrenetafusp is under investigation in clinical trial NCT04262466 (Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors).
Synonyms: Immunoglobulin, anti-(human CD3 antigen ε-chain) (human-Mus musculus single-chain Fv fragment VL-((GGGGS)4GGGS)-VH) fusion protein with peptide linker (GGGGS) fusion protein with T-cell receptor β chainDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalModifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072
VEGFR 2 Kinase inhibitor I
go.drugbank.com/drugs/DB17061ExperimentalSynonyms: Vegf receptor 2 kinase inhibitor i